Condition
SLL clinical trials and research
As of November 12, 2026, Find a Trial lists 6 SLL clinical trials that are recruiting, at sites in 24 countries (most in United States (4), Germany (2), Spain (2)). By phase: Phase 3 (2), Phase 2 (1), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 6Clinical trials
- 24Countries
Newest SLL clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Rocbrutinib versus pirtobrutinib for adults with relapsed or refractory CLL/SLL after a covalent BTK inhibitor | Phase 3 | Skokie, Illinois and 6 other locations | Recruiting | Jan 15, 2026 |
| Anti‑CD19 CAR‑T plus a BTK inhibitor for newly diagnosed high‑risk CLL/SLL | — | Xuzhou, Jiangsu | Recruiting | Aug 13, 2025 |
| Epcoritamab given after 2nd-generation BTK inhibitors for CLL/SLL | Phase 2 | Cincinnati, Ohio | Recruiting | Aug 7, 2025 |
| Comparing two treatments for relapsed chronic lymphocytic leukemia | Phase 3 | Springdale, Arkansas and 105 other locations | Recruiting | Jul 17, 2023 |
| New treatment for patients with relapsed or refractory chronic lymphocytic leukemia | Phase 1 | Boston, Massachusetts and 3 other locations | Recruiting | Jan 11, 2021 |
| Registry for patients with chronic lymphocytic leukemia and related conditions | — | Dresden, Saxony | Recruiting | Aug 11, 2016 |
All recruiting trials (6)
-
Rocbrutinib versus pirtobrutinib for adults with relapsed or refractory CLL/SLL after a covalent BTK inhibitor
This compares rocbrutinib and pirtobrutinib to see which works better and is safer for adults whose CLL or SLL returned or didn't respond after a covalent BTK inhibitor.
-
Anti‑CD19 CAR‑T plus a BTK inhibitor for newly diagnosed high‑risk CLL/SLL
We will try combining anti‑CD19 CAR‑T cells with a BTK inhibitor as first‑line treatment for people newly diagnosed with high‑risk CLL or SLL.
-
Epcoritamab given after 2nd-generation BTK inhibitors for CLL/SLL
This trial will try giving subcutaneous epcoritamab for up to 12 cycles to adults with CLL/SLL who have been on a second‑generation BTK inhibitor for at least 12 months to see if it can deepen responses to a complete remission with undetectable MRD so therapy can be stopped.
-
Comparing two treatments for relapsed chronic lymphocytic leukemia
This study is testing if a new combination of two drugs, nemtabrutinib and venetoclax, can help people with relapsed chronic lymphocytic leukemia live longer without their cancer getting worse compared to the usual treatment.
-
New treatment for patients with relapsed or refractory chronic lymphocytic leukemia
This study is testing a new treatment called CAP-100 for people with chronic lymphocytic leukemia who haven't had success with other therapies.
-
Registry for patients with chronic lymphocytic leukemia and related conditions
This study is tracking patients with chronic lymphocytic leukemia and similar conditions to see how well different treatments work and what long-term effects they might have.
Related topics
Quick answers
How many SLL clinical trials are recruiting right now?
6, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 24 countries. The most sites are in United States (4 trials), Germany (2 trials), Spain (2 trials), China (1 trial), Argentina (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 2, Phase 2: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.